Alzchem Group AG seamlessly builds on strong business performance in 2023
with EBITDA growth of 31.7% in first quarter 2024

EQS-News: Alzchem Group AG / Key word(s): Quarterly / Interim Statement
Alzchem Group AG seamlessly builds on strong business performance in 2023
with EBITDA growth of 31.7% in first quarter 2024

30.04.2024 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Alzchem Group AG seamlessly builds on strong business performance in 2023
with EBITDA growth of 31.7% in first quarter 2024

  * Result for the period increases significantly by 58.7% to EUR 12.2
    million

* Strong free cash flow of EUR 26.6 million

* Management Board confirms forecasts for the full year 2024

Trostberg, April 30, 2024 - Alzchem Group AG, a vertically integrated
specialty chemicals supplier with a leading market position in selected
niche markets, reports a successful start to the fiscal year 2024. With
consolidated sales of EUR 150.1 million in the first quarter, the company
was able to confirm the previous year's strong level of EUR 150.4 million.
As in the full year 2023, the Specialty Chemicals business proved to be a
key success factor, achieving significant growth in both sales (+8.4%) and
EBITDA (+41.6%). The Specialty Chemicals growth segment thus successfully
compensated for the expected decline in sales and EBITDA (-14.0% and -35.2%
respectively) in the Basics & Intermediates segment. The Human Nutrition
(Creapure®), Animal Nutrition (Creamino®) and Defense ((nitroguanidine)
divisions in particular performed strongly in the first three months of
2024. By contrast, business in the Custom Manufacturing segment
(multi-purpose plants), which is significantly influenced by the general
economic situation in the chemical industry, and in nitriles, due to
persistently strong competition from Asia, remained challenging.

The strategic optimization of the product mix towards higher-margin
specialty chemicals is impressively reflected in the earnings performance in
the first quarter of 2024. At EUR 24.9 million, Alzchem was able to increase
Group EBITDA by 31.7 % (previous year: EUR 18.9 million). Based on the
stable sales development, the EBITDA margin increased from 12.6% to 16.6%.
The result for the period climbed by 58.7% quarter-on-quarter from EUR 7.7
million to EUR 12.2 million. The scaling of plant expansions, particularly
in the Human Nutrition division, had a very positive effect on earnings. The
Animal Nutrition and Defense divisions also made important contributions to
earnings. In addition, the fact that the manufacturing costs of products in
the Specialty Chemicals segment are significantly less affected by the price
of electricity than in the Basics & Intermediates segment also has a
generally positive effect on earnings. In the reporting period, electricity
prices allowed price reductions for customers, particularly in the more
electricity-intensive Basics & Intermediates segment, although this is
reflected in the lower sales of this segment.

The Alzchem Group's financial position also developed very positively in the
first quarter of 2024. The operating cash flow increased from EUR 10.2
million to EUR 33.5 million, which is due in particular to the growth in
EBITDA and the reduction in working capital. Although investments rose from
EUR 4.8 million to EUR 6.9 million, free cash flow rose to EUR 26.6 million,
which is almost five times the previous year's figure of EUR 5.4 million.
This development ultimately also led to a sharp increase in cash and cash
equivalents.

Andreas Niedermaier, CEO of Alzchem Group AG: "Our consistent transformation
towards specialty chemicals continues to bear fruit, as the successful start
to the fiscal year 2024 impressively demonstrates. This applies both to our
key figures achieved in the first quarter and in view of the continuing high
demand for our products. We have therefore recently decided on a further
incremental expansion of our creatine production capacities. We are
therefore confident about the rest of the year."

Based on the good business development in the first three months, the
Management Board confirms its forecasts for the full year 2024. Accordingly,
Group sales are expected to increase from EUR 540.6 million to around EUR
570 million and Group EBITDA from EUR 81.4 million to around EUR 90 million.

The detailed quarterly statement is available for download on the website
www.alzchem.com in the Investors/Publications section.

About Alzchem
Alzchem is a globally active specialty chemicals company that is one of the
market leaders in most of its fields of activity. Alzchem benefits from the
three very different global developments climate change, population growth
and longer life expectancy in a unique way. Alzchem products can offer
attractive solutions for achieving the resulting social goals in a multitude
of different applications.

The company sees interesting growth prospects for itself in the areas of
human and animal nutrition and agriculture in particular. As a result of
population growth, it is necessary to achieve efficient food production.
Pharmaceutical raw materials and creatine products can contribute to a
healthy old age as life expectancy increases. Alzchem is facing up to the
goal of sustainability arising from climate change in the field of renewable
energies and across the entire company. The fields of fine chemicals and
metallurgy offer just as great a perspective.

Alzchem Group AG's broad product range includes dietary supplements,
precursors for PCR tests and pharmaceutical raw materials. These offerings
are the company's response to global trends and developments. Alzchem is
ideally positioned in this respect and considers itself well prepared for an
environmental future and global developments.

The company employs around 1,690 people at four production sites in Germany
and a plant in Sweden, as well as three sales companies in the USA, China
and England. Alzchem generated Group sales of EUR 540.6 million and EBITDA
of EUR 81.4 million in 2023.


---------------------------------------------------------------------------

30.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Alzchem Group AG
                   Dr.-Albert-Frank-Str. 32
                   83308 Trostberg
                   Germany
   Phone:          +498621862888
   Fax:            +49862186502888
   E-mail:         ir@alzchem.com
   Internet:       www.alzchem.com
   ISIN:           DE000A2YNT30
   WKN:            A2YNT3
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Stuttgart
   EQS News ID:    1892299

End of News EQS News Service
---------------------------------------------------------------------------

1892299 30.04.2024 CET/CEST